Related Experiment Video
Updated: Nov 7, 2025
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men
1Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, 9112102, Israel.
Abstract:
We would like to be able to design Pt(IV) prodrugs that can overcome resistance and minimize side effects. Unlike with the early exploration of Pt(II) anticancer agents where clear structure-activity relationships were defined, even after more than two decades of research on Pt(IV) prodrugs, there is no roadmap that can point us to the holy grail. Despite many excellent rational endeavors, we still have not found the "right" two axial ligands to append to the Pt(IV) derivatives of platinum(II) drugs that will "make platinum great again". So far this proved elusive, indicating that the design of Pt(IV) prodrugs is a difficult and frustrating task. Despite our better understanding of the biological processes and availability of advanced technologies, even our sophisticated rational plans often leave us disappointed and frustrated because at the end of the day, we are not able to outsmart the cancer cells or the mice, and just like Rosenberg, we might need to be rescued by serendipity.
Insights
Designing effective platinum(IV) (Pt(IV)) prodrugs remains challenging. Researchers seek specific axial ligands to improve platinum-based cancer therapy, overcoming resistance and side effects, but a clear design strategy is still elusive.
Area of Science:
- Oncology
- Medicinal Chemistry
- Drug Design
Background:
- Platinum(II) anticancer agents have well-defined structure-activity relationships.
- Platinum(IV) (Pt(IV)) prodrugs offer potential advantages but lack clear design guidelines.
- Overcoming drug resistance and minimizing side effects are key goals in platinum-based chemotherapy.
Purpose of the Study:
- To explore the design of novel platinum(IV) prodrugs for enhanced cancer therapy.
- To identify optimal axial ligands for Pt(IV) derivatives to improve efficacy.
- To address the challenges and frustrations in developing successful Pt(IV) anticancer agents.
Main Methods:
- Review of existing research on Pt(IV) prodrug development.
- Analysis of structure-activity relationships in platinum-based anticancer drugs.
- Discussion of rational design strategies and their limitations.
Main Results:
- Despite extensive research, a definitive roadmap for Pt(IV) prodrug design is still missing.
- The selection of axial ligands for Pt(IV) complexes remains a significant hurdle.
- Current rational design approaches have not consistently yielded superior outcomes compared to Pt(II) drugs.
Conclusions:
- The design of Pt(IV) prodrugs is a complex and often frustrating endeavor.
- Achieving therapeutic breakthroughs may require a combination of rational design and serendipitous discovery.
- Further research is needed to overcome current limitations in Pt(IV) prodrug development for cancer treatment.
More Related Videos
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
